Kyong-Hwa Park1, Yoon Ji Choi1, Kwan-Woo Kim2, Kyung-Han Ro2, Chang Ho Kang3, Sang-Heon Song4, Jong Hoon Park5. 1. Division of Oncology/Hematology, Departments of Internal Medicine, Korea University Anam Hospital, Seoul. 2. Department of Orthopedic Surgery, Korea University Anam Hospital, Seoul. 3. Department of Radiology, Korea University Anam Hospital, Seoul. 4. Department of Orthopedic Surgery, Myung Ji Hospital, Gyeonggi-do, Republic of Korea. 5. Department of Orthopedic Surgery, Korea University Anam Hospital, Seoul pjh1964@hanmail.net.
Abstract
OBJECTIVE: To elucidate the clinical benefit and safety of low-dose chemotherapy using methotrexate and vinblastine in patients (mostly adults) with progressive and/or symptomatic fibromatosis. METHODS: Patients were enrolled if they were treated with methotrexate and vinblastine chemotherapy for recurrences after surgical excision or newly diagnosed aggressive fibromatosis that was not amenable to surgical resection at the Korea University Medical Center from May 2008 to February 2016. RESULTS: Twenty-two patients were treated with this regimen, and 21 were eligible for safety and efficacy analysis. Eleven (52%) of 21 patients showed a documented partial response (PR), and 11 showed stable disease (SD) by the end of treatment. All the patients who achieved PR reported a significant reduction in pain and improvement in the function of the affected lesions. Median progression-free survival was not reached at the time of analysis. The most common adverse event was abnormalities of the liver transaminases (overall 84.2%). The most common grade 3 or higher toxicity was neutropenia (36.8%), but no febrile neutropenic event was observed. The elevated levels of transaminases were normalized by reducing the dose of methotrexate or delaying treatment. CONCLUSIONS: Low-dose chemotherapy with methotrexate and vinblastine for 1 year was effective and well tolerated by adult patients with aggressive, recurrent fibromatosis.
OBJECTIVE: To elucidate the clinical benefit and safety of low-dose chemotherapy using methotrexate and vinblastine in patients (mostly adults) with progressive and/or symptomatic fibromatosis. METHODS:Patients were enrolled if they were treated with methotrexate and vinblastine chemotherapy for recurrences after surgical excision or newly diagnosed aggressive fibromatosis that was not amenable to surgical resection at the Korea University Medical Center from May 2008 to February 2016. RESULTS: Twenty-two patients were treated with this regimen, and 21 were eligible for safety and efficacy analysis. Eleven (52%) of 21 patients showed a documented partial response (PR), and 11 showed stable disease (SD) by the end of treatment. All the patients who achieved PR reported a significant reduction in pain and improvement in the function of the affected lesions. Median progression-free survival was not reached at the time of analysis. The most common adverse event was abnormalities of the liver transaminases (overall 84.2%). The most common grade 3 or higher toxicity was neutropenia (36.8%), but no febrile neutropenic event was observed. The elevated levels of transaminases were normalized by reducing the dose of methotrexate or delaying treatment. CONCLUSIONS: Low-dose chemotherapy with methotrexate and vinblastine for 1 year was effective and well tolerated by adult patients with aggressive, recurrent fibromatosis.
Authors: M Libertini; I Mitra; W T A van der Graaf; A B Miah; I Judson; R L Jones; K Thomas; E Moskovic; Z Szucs; C Benson; C Messiou Journal: Clin Sarcoma Res Date: 2018-05-14
Authors: Sarah Kern; Ines Truebenbach; Miriam Höhn; Jan Gorges; Uli Kazmaier; Stefan Zahler; Angelika M Vollmar; Ernst Wagner Journal: Pharmacol Res Perspect Date: 2019-01-22
Authors: Katrina M Ingley; Sally M Burtenshaw; Nicole C Theobalds; Lawrence M White; Martin E Blackstein; Rebecca A Gladdy; Seng Thipphavong; Abha A Gupta Journal: Cancer Med Date: 2019-07-13 Impact factor: 4.452
Authors: Elena Palassini; Bruno Vincenzi; Andrea Napolitano; Salvatore Provenzano; Chiara Colombo; Marco Vitellaro; Antonella Brunello; Giuseppe Badalamenti; Margherita Nannini; Toni Ibrahim; Peter Hohenberger; Silvia Gasperoni; Spyridon Gennatas; Robin L Jones; Nadia Hindi; Javier Martin-Broto; Mariella Spalato Ceruso; Marianna Silletta; Angelo Paolo Dei Tos; Alessandro Gronchi; Silvia Stacchiotti; Daniele Santini; Giuseppe Tonini Journal: ESMO Open Date: 2020-01